Cardiovascular Risk Factors and Peripheral Arterial Disease
A 62-year-old man with intermittent claudication was referred for vascular risk factor modification. He had no history of myocardial infarction (MI) or stroke. He was smoking 20 cigarettes/day. His family history was negative for premature vascular events in first degree relatives. He was not taking any medication. He was advised to start aspirin 75 mg/day, but he stopped taking these tablets because of “stomach discomfort”. The patient’s total cholesterol was 228 mg/dL (5.9 mmol/L). His blood pressure required treatment with amlodipine and a thiazide diuretic. The patient eventually stopped smoking after referral to the smoking cessation clinic in our hospital.
Fasting plasma glucose.
Urine glucose to make a diagnosis of diabetes mellitus.
Fasting serum triglycerides.
Fasting serum high-density lipoprotein cholesterol (HDL-C).
Thyroid function tests.
- 1.Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207–74.CrossRefPubMedGoogle Scholar
- 3.Alberti KG, Eckel RH, Grundy SM, International Diabetes Federation Task Force on Epidemiology and Prevention. Hational Heart, Lung, and Blood Institute. American Heart Association; World Heart Federation. International Atherosclerosis Society; International Association for the Study of Obesity, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. National Heart, Lung, and Blood Institute. American Heart Association. World Heart Federation. International Atherosclerosis Society. and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRefPubMedGoogle Scholar
- 5.Colhoun HM, Betteridge DJ, Durrington PN, CARDS investigators, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.CrossRefPubMedGoogle Scholar
- 7.Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, Bilianou H, Anagnostopoulou K, Panotopoulos G. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011;9:258–70.CrossRefPubMedGoogle Scholar
- 12.Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344.CrossRefPubMedGoogle Scholar
- 17.De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Third Joint Task Force of European and Other Societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601–10.CrossRefPubMedGoogle Scholar
- 23.Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–79.CrossRefPubMedGoogle Scholar
- 31.Rahman M, Brown CD, Coresh J, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group, et al. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the antihypertensive and lipid-lowering treatment to prevent Heart Attack Trial. Arch Intern Med. 2003;164:969–76.CrossRefGoogle Scholar
- 32.Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728–34.CrossRefPubMedPubMedCentralGoogle Scholar